CD58 and acute myeloid leukemia: discovered that diminished CD58 expression correlates with unfavorable OS in cytogenetically normal acute myeloid leukemia (CN-AML) patients and suggested a combined WT1 and CD58 model for prognostic risk evaluation in CN-AML patients, which complements existing prognostic assessment methodologies for CN-AML (61).